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Summary 
The leukocyte differentiation antigen, CDS0, has been recently identified as the intercellular adhesion 
molecule 3 (ICAM-3), the third counter-receptor oflenkocyte function-associated antigen 1 (LFA-1). 
This molecule seems to be specially involved in the adhesion events of the initial phases of the 
immune response. To characterize the role of CD50 in leukocyte interactions, the different molecular 
events induced after cross-linking of CDS0 on T cell-derived  Jurkat cell line have been analyzed. 
When cells were incubated with anti-CDS0 mAbs and cross-linked  with polyclonal goat anti-mouse 
immunoglobulins, a rise in intracellular  calcium  concentration ([CaZ+]i) was observed.  This 
increase in [Ca2+]i was mainly due to the uptake of extracellular C# + . This Ca  2+ flux involved 
tyrosine phosphorylations  and was further increased by CD3 costimulation.  These data, together 
with those obtained by phosphotyrosine (P-Tyr) immunoprecipitation and in vitro kinase assays, 
suggested the involvement of protein-tyrosine kinases (PTK) in CD50 transduction pathways. 
By using specific antisera, the presence of p56 ld' and p59 ryn protein tyrosine kinases (FTK) was 
dearly demonstrated in the CD50 immunoprecipitates. These findings suggest that the interaction 
of CD50 with its natural ligand (LFA-1) may result in T lymphocyte activation events, in which 
CDS0 could play a very active role after antigen triggering. 
T 
he immune system, composed of redrculating cells, uses 
a dynamic and complex group of membrane molecules 
involved in cell-cell interaction mechanisms that are related 
at different degrees to antigen-dependent proliferation  (1). 
These intercellular interactions are also especially relevant in 
several steps of inflammatory and immune responses. Among 
these steps, functions such as lymphocyte traffic between lym- 
phoid organs and the bloodstream, lymphocyte migration 
to sites of injury, and antigen recognition are to be included 
(2). Intercellular adhesion is mediated by many different mol- 
ecules, CD50 being a molecule that plays a prominent role 
in cell adhesiveness.  This molecule has recently been identified 
by us as intercellular  adhesion molecule 3 (ICAM-3) t (3), 
and it has been described as the third counter-receptor for 
the leukocyte integrin leukocyte function-associated antigen 
1 Abbreviations used in thlspaper: [Ca2+]i, ititracellular calcium concentra- 
tion;  GAM, goat  anti-mouse  immunoglobulins; ICAM,  intercellular 
adhesion molecule; IP3, D-myo-inositol 1,4,5,-trisphosphate; LFA-1, 
leukocyte-associated antigen 1; PKC, protein kinase C; PTK, protein 
tyrosine kinase. 
1 (LFA-1) (4, 5). Moreover, CD50 seems to be a relevant 
molecule involved in leukocyte interactions  (5, 6). 
CD50 (ICAM-3) was described as a 120-kD, highly ex- 
pressed, and hematopoietically restricted leukocyte surface an- 
tigen during the IV International Workshop on Human Leu- 
kocyte Differentiation Antigens (7), being originally defined 
by two mAbs (101-1D2 and 140-11) that were produced and 
characterized  in our laboratory. The initial description of CD50 
mAbs inhibiting allorecognition (6) suggested  that CD50 
could be a relevant molecule involved in leukocyte interac- 
tions. The finding that CD50 became rapidly and transiently 
phosphorylated on serine residues (8) upon stimulation ei- 
ther by PMA or T  cell receptor cross-linking  suggested  a 
biochemical regulation of its function. The analysis of CD50 
eDNA clones (9-11) showed the highest homology with 
ICAM-1 and ICAM-2, especially in their extracellular do- 
mains.  However,  comparison of the intracellular  regions 
showed a low similarity, suggesting a different function for 
the intracytoplasmic domain of each different ICAM mole- 
cule (9, 11). Indeed, five serine residues in CDS0 cytoplasmic 
region are, probably, the residues that become phosphorylated 
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induced by PMA or CD3 (8). This phosphorylation could 
be a way of controlling a possible CD50 function,  such as 
the LFA-1 phosphorylation in response to phorbol ester (12). 
Unlike  its  homologous  ICAM-1  and  ICAM-2,  this  new 
member of the Ig gene superfamily is highly expressed on 
resting lymphocytes. This fact strongly suggested that CD50 
is preferentially used by lymphocytes in the LFA-l-mediated 
binding during the initial interactions of immune recogni- 
tion and lymphocyte activation (5, 9). Furthermore, its lack 
of expression in endothelial cells (9, 10) leads us to assume 
that its possible role in the leukocyte-endothelial cell is indirect. 
It has been repeatedly described that, in the ICAM-1/LFA-1 
interaction, the LFA-1 plays the most important role in signal 
transduction (13-17).  This signaling pathway through LFA-1 
involves calcium mobilization, phosphoinositide hydrolysis, 
amplification of CD3-dependent IL-2 production, and prolifer- 
ation and enhancing antigen presentation in B cells. Whereas 
direct intracellular  signaling pathways through LFA-1 have 
been extensively described, there are few data about trans- 
ducing effects through ICAM-1 (18,  19) and ICAM-2 (20). 
All these data suggested that the main functional role of both 
ICAM-1 and ICAM-2 was their binding with LFA-1 which 
triggered some tramduction signals that affected directly other 
stimulatory surface proteins, enhancing cell activation. If one 
considers the high homology of CD50 with ICAM-1 and 
ICAM-2,  and the fact that little is known about the func- 
tional involvement of CD50 in cell activation it could easily 
be assumed that CDS0, like ICAM-1 and ICAM-2, would 
play only a secondary role in signal transduction.  However, 
since its first description (3), the important  differences,  de- 
scribed above (cell distribution and cell induction, intracyto- 
plasmic domain, phosphorylation by PKC stimulation), sug- 
gested that  CD50 could play a more active role in  signal 
transduction  than  ICAM-1  or ICAM-2. 
To analyze the role of CD50 in immune interactions, the 
ability of anti-CD50 mAbs to transduce signals into Jurkat 
cells, a T-derived cell line, was studied. In this study, direct 
biochemical and cellular evidences are described showing that 
CD50 (ICAM-3) is a molecule capable of transducing signals 
across the plasma membrane of these cells.  More precisely, 
our results show a direct relationship between two protein 
tyrosine kinases (FTKs), p56  kk and p59~ (two nonreceptor 
PTKs of the src family), and CD50 molecule, suggesting their 
involvement in the CD50 signaling pathway. These data con- 
tribute to a better understanding of CDS0 (ICAM-3) activa- 
tion pathways and present CDS0 as a new costimnlatory mol- 
ecule with a probable enhancing role in immune response. 
Materials  and Methods 
Antibodies and CeULin~  The following murine mAb to human 
antigens were used at the indicated concentrations:  101-1132 (anti- 
CD50, IgG1) (6); 140-11 (anti-CD50, IgG2b) (6); 152-2Dll (anti- 
CD50, IgG1) 0); 143-14 (CD27, IgG2a) (21); RM3A5 (anti-CD54, 
IgG2a) (22); 72-5D3 (anti-CD45,  IgG1) (23); Cris-7 (anti-CD3, 
IgG1) (23); 124-1I)1 (anti-CO7,  IgG1) (24); 133-1G6 (IgM) (25); 
and nonhinding NS1 ascites as a control (IgG1). All antibodies were 
purified by protein A affinity chromatography. Second step poly- 
clonal goat anti-mouse Ig (GAM) (affinity purified) was purchased 
from Tago, Inc. (Burlingame, CA). P-Tyr (Ab-1), anti-phospho- 
tyrosine (P-Tyr) mAb was obtained from Oncogene Science, Inc. 
(Manhasset, NY). Rabbit polydonal antiserum to p56  ~  (26) and 
p59~  (27) were  kindly  provided  by  Dr.  K.  M.  l~lmutter 
(University of Washington,  Seattle, WA). The Jurkat T-derived 
lymphobhstoid cell line was obtained from the European Collec- 
tion of Cultured Cell Lines (Salisbury, UK) and was maintained 
in culture in RPMI 1640 medium supplemented with 10% FCS. 
[Ca2+]i Measurements.  INDO  1-AM cell labeling  was  per- 
formed according to a standard protocol (28). Briefly, Jurkat cells 
were washed twice in INDO 1 buffer A (I-IBSS medium with 10 
mM  Hepes,  pH  7.0),  counted,  and  resuspended  at  5  x  106 
cells/ml. The fluorescent Ca  2. indicator INDO 1-AM (Molecular 
Probes, Inc., Eugene, OK) was added to cell lines to 12.5 #M. 
After a 30-rain incubation  at 37~  the same volume of INDO 
1 buffer B (HBSS with 10 mM Hepes and 5% FCS, pH 7.4) was 
added and reincubated for 30 min at 37~  Then, cells were washed 
twice with INDO 1 buffer C (HBSS with 10 mM Hepes, 10 #M 
DNAase, and 5% FCS, pH 7.2), counted, and resuspended at 5 x 
10  ~ cells/m1 at room temperature. Several minutes before the stim- 
ulation,  cells were resuspended at 5  x  10  s cells/m1 in INDO 1 
buffer C and maintained at 37~  Cells were incubated with the 
different mAb for 15 rain, and then washed twice. Cross-linking 
stimulation of mAbs was made with a second step polydonal GAM, 
during the analysis. In some experiments CaCI2 was omitted from 
the INDO 1 buffer C medium, and EGTA 100 #M added instead. 
After the complete response without extracellular Ca  2.,  10 #M 
CaC12 was added to the medium. Both Genistein and Herhimycin 
A (both from Calbiochem, LaJolh, CA) were used as PTK inhibi- 
tots. In the experiments where Genistdn was used, this inhibitor 
was added 30 min before the analysis at 150, 75, 25, and 7.5 #M. 
In the experiments where Herbimycin A was used, cells were prein- 
cubated with this PTK inhibitor 16 h before the assay. Both inhibi- 
tors were maintained throughout the assay. Fluorescent measure- 
ments were carried out on a FACStar-plus  |  (Becton Dickinson & 
Co., Mountain  View, CA), using an argon ion laser, focused in 
the UV (351-363 nm).  INDO 1-AM emissions were detected at 
405/22 and 485/22 nm and analyzed by Chronys software (Becton 
Dickinson  & Co.) a software package that allows the evaluation 
of the mean INDO 1-AM violet/blue fluorescence ratio vs. time. 
o-m2c-Inositol 1,4,5 Trisphosphate  (IP3) Determination.  Jurkat cells 
on HBSS medium (BSS + 50 mM Hepes + 5% FCS) were treated 
with 50 #g/ml of anti-CD50  (152-2Dll),  1 rig/m1 of anti-CD3 
(positive control),  or GAM alone (negative control),  for 20 rain 
at 4~  Excess antibodies were removed  by centrifugation and Pellets 
were suspended in 1 ml of  HBSS medium with or without 20 #g/m1 
of GAM. Incubation  was carried out for the indicated time and 
stopped by addition of 200/zl ice-cold perchloric acid 20%. After 
a 20-min incubation  on ice, samples were centrifuged  (2,000 g) 
and supernatants were titrated  to pH 7.5 with 1.5 M KOH and 
60 mM Hepes buffer. IP3 levels were measured with IP3 [3I-I] assay 
system (Amersham International, Little Chalfort, UK) by the com- 
Petition  between tested  unlabeled  IP3  and  a fixed quantity  of 
[3H]IP3 for a bovine adrenal binding protein with a limited number 
of binding  sites. 
~2P-Orthophosphate Radiolabeling and P-Tyr lramunoprecipitation 
Analysis.  After washing twice in phosphate-free medium (20 mM 
Hepes,  10 mM dextrose,  1 mM CaC12, 5 mM KC1, 150 mM 
NaC1, 1 mM MgCI2, I mM MgSO4, and 20 mM NaHCO3, pH 
7.2),  2  x  106 ceUs/ml were suspended  in  this  phosphate-free 
medium  supplemented  with 10% dialyzed FCS containing  500 
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tional). Radiolabding was carried out for 3 h in 6-well tissue cul- 
ture plates (Costar Corp., Cambridge, MA) at 37~  in 5% CO2 
according to a standard protocol (29). Once labeled, ceils were in- 
cubated for 50 rnin with each mAb. Excess antibodies were removed 
by centrifugation and pellets were resuspended in 1 ml of medium 
with 25/~g/ml of GAM. Incubation was carried out for 5 min 
and then, cells were disrupted at 4~  for 30 mill in a lysis buffer 
containing protease and phosphatase inhibitors (30). After four 
clearing cycles  with an unrelated mAb plus protein A-Sepharose, 
supernatants were adjusted to contain identical acid-insoluble ra- 
dioactivity and incubated for 1-2 h with 10/~1 of  P-Tyr (Ab-1) anti- 
P-Tyr mAb. Then, lysates  were incubated for 1-2 h with 50/~1 pro- 
rein A-Sepharose packed beads adsorbed with a rabbit anti-mouse 
Ig serum (Dako, Glostrup, Denmark). The resulting immune corn- 
pieces were washed, eluted, and analyzed by SDS-PAGE (31) in 
10% polyacrylamide slab gels at 30 mA/gel.  The gel was dried 
and exposed to Kodak X-Omat AK films with intensifying screens 
at -80~  For assessing molecular masses, a standard 14C-labeled 
protein mixture (Amersham International)  was inchded in the gels. 
In Vitro  Kinase Assay.  Solubilization and kinase reactions were 
performed as previously described (32), with some modifications. 
Briefly, ceils were harvested and solubilized at 2  x  107 ceils/ml 
in either 1% Triton X-100 lysis  buffer (1% Triton X-100/150 mM 
NaC1 with I mM sodium orthovanadate +  1 mM EDTA +  leu- 
peptin [10 mg/ml]  +  aprotinin [10 mg/ml]  +  25 mM p-nitro- 
phenyl-p-guanidinobenzoate)  or in 1% digitonin lysis buffer (1% 
digitonin/150 mM NaC1/50 mM Hepes, pH 7.5, with the above 
inhibitors; digitonin was prepared as described by Oettgen et al. 
[33]). Soluble lysates  from 107 cells were incubated at 4~  for 1 h 
with  different  mAb  and  then,  immunoprecipitated  for  1  h 
with protein A-Sepharose  (Pharmacia  LKB,  Uppsah, Sweden).  After 
immunoprecipitation,  immune complexes were washed in lysis 
buffer with appropriate  detergent but without EDTA. In some  cases, 
1 M MgCh lysis buffer was used for washing out associated mol- 
ecules (3). Immunocomplex kinase assays  were performed by incu- 
bation at 4~  for 15 min in 50 t~l kinase buffer (150 mM NaCI 
+  20 mM Hepes, pH 7.5,  +  5 mM MnClz +  5 mM MgC12 + 
1 mM ATP +  10 mCi of 3"-[32P]ATP). The reaction was stopped 
with lysis  buffer containing the appropriate detergent and 20 mM 
F_DTA. Immunocomplezes  were washed twice in lysis  buffer,  ehted 
in SDS sample buffer and analyzed by SDS-PAGE 8% (30). 
Phosphoamino Acid Anal)sis.  3~P-labded  proteins were electro- 
eluted from excised  bands of  polyacrylamide  gels, precipitated  with 
cold acetone/NH3 (5.3:0.3) and hydrolyzed in 0.2 ml 6 M HC1 
at 110~  for 2 h. Acid-hydrolyzed  samples were dried, resuspended 
in 0.2 ral HzO, and dried again. The residue was then resuspended 
in  10  /~1 in  electrophoresis buffer  (pyridine/acetic acid/water, 
5:50:945), pH 3.5. Samples of 2-10/~1 were spotted on cellulose- 
coated plates (E. Merck, Darmstadt,  Germany), next to 1/~1 of 
a phosphoamino  acid standard solution  (phosphoserine, phos- 
phothreonine, and phosphotyrosine, milligram per milliliter each), 
and analyzed by one-dimensional thin-layer electrophoresis (1000 
V, 45 rain). Nonradioactive standards were detected with 0.25% 
ninhydrin in ethanol and radiolabeiled  phosphorylated amino acids 
by autoradiography. 
CD50 lmmunoFrecipitation  and PTK (Western) Blot Analysis.  To 
control the eCficiency  of immunoprecipitation, we previously la- 
beled cells with  12sI. For  this  radiolabeling, Jurkat  cells were 
surface-labeled with 12sI using  Iodogen  (Pierce Chemical Co., 
Rockford, IL) (34). After labeling, 2 x  107 Jurkat cells were lysed 
in 1 ml lysis buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaC1, 
1 mM EDTA, 1 mM EGTA, 0.5% NP-40, I raM NaF, I mM PMSF, 
20/tl/ml egg white trypsin inhibitor, 1/tg/ml leupeptin, and 1 
/~g/ml pepstatin) for 30 min on ice. Nuclei and insoluble debris 
were removed  by centrifugation at 14,000g for 10 min and lysates 
precleared with protein A-Sepharose (Pharmacia LKK Uppsah, 
Sweden), prewashed  in lysis  buffer. Immunoprecipitation was per- 
formed with  the  indicated mAb,  coupled  to  CNBr-activated 
Sepharose CI~4B (Pharw~_~_'_~_  LKB) for I h at 4~  washed six times 
with washing buffer (50 mM Tris-HCl, 150 mM NaC1, 5 mM 
EHEA, pH 8.0, 0.05% NP-40, 0.05% SDS, and with the above 
iuln~itors) and duted with 2x SDS reducing sample  buffer. Samples 
were counted with a 3' counter. The same quantity ofcpm for each 
sample was loaded in each lane and samples were run on 8% SDS- 
PAGE 01), and transferred by electroblotting (4 mA/cm  2) with 
glycine transfer buffer (39 mM glycine, 48 mM Tris-base, 1.3 mM 
SDS, and 20% methanol) to nitrocellulose. SDS-PAGE molecular 
weight standards  (Bio-Rad  Laboratories,  Richmond, CA) were used. 
After incubating filters with blocking solution (5% ovalbumin 
[Sigma Chemical Co., St. Louis, MO] and 3% nonfat milk protein 
in PBS) overnight at 4~  blots were incubated with anti-p56  ~ 
and anti-p59~  diluted to 1:1,000 in blocking solution for 1 h at 
20~  After washing with 0.25% gehtin in PBS, filters were in- 
cubated with goat anti-rabbit coupled to peroxidase in blocking 
solution for 1 h at 20~  Filters were washed again with 0.25% 
gelatin in PBS, and the Western blots were developed  using Amer- 
sham's enhanced chemiluminescence  (ECL) reagent (Amersham  In- 
ternational). 
Results 
CD50 (ICAM-3) Cross-linking Induces a  Transient Increase 
in Intracellular Calcium Levels of  Jurkat Cells.  The ability of 
three different anti-CD50 mAbs (101-1132, 152-2Dll,  and 
140-11) to induce a Ca  z+ mobilization across the membrane 
of Jurkat cells was analyzed. It has been previously shown 
that these three mAbs recognize different epitopes of the CD50 
(ICAM-3) (3).  The results in Fig. 1 show dearly that two 
of them, namely 101-1D2 and 152-2Dll, are able to induce 
a transient increase in [Ca2+]i by their binding and cross- 
linking to Jurkat cells, whereas 140-11 does not induce any 
change. The Ca  2+ mobilization obtained with the 101-1132 
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Figure  1.  Ca  2+ mobilization  after  CD50 cross-linlrin  8. Effect ofanti- 
CD3: Cris 7, 1 ng/ml (O-O);  and three anti-CD50s, 50 #g/ml: 152- 
2Dll (A-A); 101-1D2 (m-m); 140-11 (A-&); cross-linkod  at 50 s with 
10 #g/ml of GAM. 
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served with the 152-2Dll mAb. The lack of response ob- 
tained with the 140-11 mAb, even at the highest dose tested 
(100/zg/ml),  confirms that this mAb and 152-2Dll and 101- 
1132 mAbs recognize different functional epitopes of CD50 
molecule.  As negative controls for calcium mobilization, several 
mAbs (tLM3A5,  124-1D1, and 133-1G6) of different sub- 
types  (IgG2a,  IgG1,  and  IgM,  respectively) recognizing 
different Jurkat membrane antigens have been used. Whereas 
the binding and cross-linking of these mAb did not induce 
any detectable [CaZ+]i  increase, the cross-linking of CD3 has 
been used as positive control for Ca  2+  mobilization  in all 
the tested situations (data not shown). The transient increase 
in [Ca2+]i obtained by CD50 cross-linking is similar to the 
effect observed by cross-linking very low doses of anti-CD3 
mAb (1 ng/ml) (Fig. 1) (at a higher dose [910 ng/ml], anti- 
CD3 mAb is able to induce an increase in [Ca 2+ ]i without 
cross-linking by GAM). A singular characteristic of the effect 
obtained with the CD50 mAb was the fact that although 
the maximum effect of CD50 cross-linking took longer to 
be reached than the one obtained by CD3 mAb, the increase 
of [Ca2+]i observed using CDS0 mAbs reached a higher and 
more sustained plateau than the plateau obtained with CD3 
mAb: CD50 effect reached its maximum level at 100-120 s 
after stimulation (70-100 s with CD3), but it was maintained 
at a high plateau (higher than CD3 stimulation)  for longer 
than 500 s. 
Dose-response experiments were performed  using different 
concentratiom of anti-CD50 mAb (Fig. 2 A) and cross-linking 
antibody  (Fig. 2  B).  The  transient  increase  [Ca2+]i was 
shown to be proportional to the amount of anti-CD50 mAb. 
A minimum effect  was observed  with a dose as low as 2/~g/ml 
and the maximum level was reached with oversaturating 
amounts of mAbs (100/~g/ml) (Fig. 2 A). Regarding the 
cross-linking antiserum, the relative increase in [Ca  2  +  ]i was 
proportional to the concentration used, reaching its highest 
level with oversaturating (50/~g/ml) amounts of GAM (Fig. 
2 B). Taking all these data into account, the doses of 50/~g/ml 
of 152-2Dll and 10/~g/ml of GAM, which were shown to 
be dearly stimulating,  were chosen as standard doses for all 
subsequent  assays. 
Simultaneous CD3 and CD50 (ICAM-3) Cross-flnleing; In- 
volveraent of Different Ca  2+ Sources.  When Jurkat cells were 
treated simultaneously  with stimulating concentrations of  both 
CD3 and CD50 mAb, plus GAM, a high increase in [Ca2+]i 
was observed (Fig. 3 A). The increase in [Ca2+]i was sharper 
than the one observed when CD3 or CD50 mAbs were used 
alone, whereas the peak of [Ca2+]i reached under these con- 
ditions was similar to the addition of the effects  of anti-CD50 
and anti-CD3  used  separately. Moreover,  the increase in 
[Ca  2+ ]i using both mAbs simultaneously was prolonged on 
a level higher than the one obtained  using CD3 or CD50 
mAb alone. Therefore, the response to both mAb seems to 
be the addition of  each separated  response, resulting in a global 
improvement of the [Ca2+]i signaling. 
To better characterize the mechanisms responsible for the 
effect of anti-CD50 mAb, Ca  2  + mobilization in Jurkat cells 
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Figure 2.  Dose-response  analyds on Ca  2+ mobilization after CD50 
cross-h~dng. (A) Calcium increases  at di~c,t~nt concentrations of 152- 
2Ol1:100 (O-O), 50 (A-A), 10 (E]-I"]), an(] 2 (B-B)/zg/m], cross- 
linked at 50 s with 10 ~tg/ml ofGAM. (B) INDO 1-AM levels after stimu- 
lation with 50/~g/ml of 152-21311 with different doses of GAM, at 0 s 
(e-e)  and 120 s (l~al) after cross-linking. 
was analyzed in Ca  2+-free, EGTA-containing medium before 
and after the CaCI2 addition (Fig. 3 B).  Under Ca  2+-free 
conditions,  a rapid increase could be observed as a result of 
Ca  2  + redistribution from intraceUular stores; however, this 
effect was shorter and smaller than the increase observed in 
medium with Ca  2+ . The characteristic sustained phteau that 
is observed stimulating with CD50 mAb and which is higher 
than the level obtained upon CD3 stimulation, disappeared 
using Ca2+-free conditions.  Subsequent addition (Fig. 3 B, 
arrow) of Ca  2  + to the medium (10 p2Vl CaCh) induced a fur- 
ther [Ca2+]i increase, as a result of the uptake of extracel- 
lular Ca  2+. This increase achieved a plateau as high as the 
one obtained using the medium with Ca  2+ . AU these data 
suggest  that the increase in Ca  2§  obtained  by anti-CDS0 
stimulation  is  mainly due to  the uptake of extracellular 
Ca  2  +. This extracellular Ca  2  § would be responsible for the 
characteristic  prolongation  of the  increase, whereby the 
Ca  2* from the internal stores would be responsible only for 
the initial increase, and even in this case in a minor way. 
To analyze the role of inositol phospholipid  hydrolysis in 
CD50 Ca  2+ mobilization, the II)3 levels on stimulated Jurkat 
cells were evaluated. After CD50 stimulation with 152-2Dll 
cross-linking, a slight but clear increase of IP3 at 15 s (Table 
1) was detected;  IP3 increase induced by CD50 mAb was 
lower than the increase induced by CD3 mAb used as posi- 
tive control. No IP3 increase was observed by using GAM 
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Figure 3.  Ca  2* mobilization after CD3 and CD50 co-eross-linking, 
and after CD50 and CD3 individual  cross-li~dng, in absence  of =tsacel- 
]u]ar Ca  2+. (A) Additional effect of the costimulation with anti-CD3 
(Cris-7) and anti-CD50 on Jurkat cell line. Cris-7 (O-O), 1 ng/ml; 152- 
2I)11 (A-A), 50/~g/ml; and 152-21)11 +  Cris-7 (m-II), 50/tg/ml + 
1 ng/ml; cross-linked at 50 s with 10/~g/ml of GAM. (B) Jurkat ceils 
were stimuhted by cross-linking CD3 and CD50 at 50 s in an INDO-1 
buffer C with 100 mM EGTA and without CaCI2 and or with 10/zM 
CaC12 was added at 300 s (arrow). Stimuhtions in presence of =tracel- 
lular Ca  2+ are also presented. Cris-7, 1 ng/m/, with (O-O) and without 
(e-e)  extracelhlar  Ca  2§  and 152-2I)11, 50/~g/ml, with (A-A) and 
without (A-A) ~tracellular Ca  z+, cross-linked at 50 s with 10/~g/ml 
of GAM. 
alone (negative control). Thus, the effect of CDS0 stimula- 
tion on IP3 levels correlated perfectly with the initial induc- 
tion of Ca  2  + mobilization. This correlation could probably 
explain the intracellular component of Ca  2+  increase. 
Ca  2+ Mobilization Induced  by  CD50 (ICAM-3) Cross-linking 
Is Mediated by Tyrosine Phosphorflation.  To further analyze 
the signal transduction pathway responsible for the effect of 
CDS0 mAb, the role of tyrosine phosphorylation on the in- 
crease in [Ca2+]i (Fig. 4) was studied. Pretreatment of Jurkat 
ceils for 30 min and throughout the assay with 7.5, 25, 75, 
and 150 #M  of Genistein showed an inhibitory effect on 
Ca  z+  mobilization. This inhibition was partial at 7.5,  25, 
and 75/~M and almost total at 150/~M (Fig. 4 A). Instead, 
the stimulatory effect of CD3 was only partially inhibited 
by Genistein (data not shown), blunting the Ca  z+ increase, 
as previously described (35).  Furthermore, pretreatment of 
Jurkat cells for 16 h with Herbimycin A at 1 #M also com- 
pletely prevented the increase in [Ca2*]i induced by CDS0 
mAbs (Hg. 4 B). As previously described (36), Herbimycin 
A also totally inhibited CD3 Ca  z + mobilization, although 
an increase in [Ca2+]i induced by A23187 ionophore was 
completely  resistant to both Genistein and Herbiraycin A (data 
not shown). 
For a better understanding of the role of PTK in Ca  z+ 
mobilization induced by CDS0 mAb, the effect of CD45 on 
this effect was analyzed.  A mAb against CD45, which is a 
molecule with phosphatase activity (37), was incubated simul- 
taneously with CDS0 mAb. A total inhibition on the CD50 
Ca  z+  increase  was observed with the co-cross-linking of 
CDS0 and CD45 mAb (Hg. 4 C). These data are in agree- 
ment with similar observations where phosphatase activity 
of CD45 was shown to inhibit analogous Ca  2+ mobiliza- 
tions dependent on kinase activity (38,  39). 
CDSO (ICAM.3) Cross.hieing Induces TFosine.Phospl~flation 
of  33- and 40-leD-specific  Substrates.  The effects of both, PTK 
inhibitors and CD45 on CDS0 induced Ca  2+ mobilization 
made us analyze the pattern of tyrosine phosphorylation after 
CDS0 cross-1/nking,  l~2-1abeled Jurkat cells (Fig.  5) were 
treated with CD50 mAb (152-2Dll) and cross-linked with 
GAM for 5 min. After immunoprecipitation  with an anti-P- 
Tyr mAb of the lysates, a remarkable increase in the tyrosine 
phosphoryhtion pattern was observed. Especially rdevant was 
the effect on a 33-kD molecule that appeared phosphorylated 
after CD3 and CD50 stimulation and was absent in the nega- 
tive control. In addition, a significant  increase in the phos- 
phorylation ofa 40-kD protein after CD50 cross-linking was 
also detected. 
CD50 (ICAM-3) mAb Coimmunoprecipitates  an Associated 
Tyrosine Kinase Activit2,: both p5# ~ and p59~ PTK Are De- 
tected in Association with CD50.  The immunoprecipitate  ob- 
tained with the three CD50 mAb were tested in an in vitro 
kinase assay. Fig. 6 A shows the pattern of phosphorylation 
Table  1.  /P3 Mobilization after Cross-linking of CDSO Stimulation (pmols/lO 6 Cells) 
0  s  15  s  30 s  1 min  2  rain  5  min  10 rain  15 rain 
GAM  0.39  0.23  0.42  0.22  0.20  0.45  0.42  0.19 
CD50  0.23  1.00  0.57  0.50  0.62  0.42  0.40  0.22 
CD3  0.40  1.20  0.75  0.58  0.50  0.45  0.39  0.41 
Jurkat cells were incubated on I-[BSS medium with 50/tg/rrd of anti-CD50 (152-2Dll), 1 ng/rrd of anti-CD3 (positive control), and GAM alone 
(negative control), for 20 rain at 4oC. Excess antibodies were removed and cells were cross-linked in 1 ml of HBSS medium with 25/~g/ml of 
GAM. Incubation was carried out for the indicated times and stopped by addition of 200/~1 ice-cold perchloric acid 20%. Samples were centrifuged 
and IP3 levels of the supernatants  were measured with IP3 3H assay system (Amersham  International). 
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Figure 4.  Ca  z  + mobilization  induced after CD50 stimulation is in- 
hibited  by Genistein  and Herbimycin  A treatment  and after  co-cross-|inking 
of CD50 and CD45. (/1) Inhibition  effect  of Genistein  at 0 (m-I), 7.5 
(@-@), 25 ([-]-[7), 75 (O-O), and 150 (A-A)/~M in CD50 stimula- 
tion. (B) Inhibition effect  of Herbimydn  A at 0 (O-O) and 1 (O-O) 
/~M. (C) Inhibition  effect  of co-cross-linking  with anti-CD45 (72-5D3) 
and anti-CD50  (152-2I)11). 152-21311  (g-m), 50/Lg/ml; 72-5D3 (F]-F]), 
50/~g/ml; 152-2Dll + 72-5D3 (A-A), 50/~g/ml + 50/~g/ml; cross- 
linked at 50 s with 10/~g/ml of GAM and (O-O) only GAM. 
obtained when 1% Triton X-100 was used as detergent. A 
specific phosphoryhtion of a 31-kD molecule was observed, 
confirming the presence of a kinase activity associated  with 
the CD50 molecule, contrasting with the lack of phosphory- 
lation after immunopredpitating with a negative control mAb 
(anti-CD27).  In  addition,  we had previously shown that 
washing in 1 M MgC12 is able to diminate all the associated 
molecules without ehting CD50 molecule from the mAb 
binding (3).  The results in Fig.  6 A  show that the kinase 
activity was duted by using  1 M  MgC12 washing buffer, 
suggesting that this kinase activity was not intrinsically due 
to the CDS0 molecuh. To assess the type of phosphoryla- 
tion, the 31-kD phosphorylated protein was hydrolyzed and 
Figure 5.  Immunoprecipita- 
tion of  Jurkat cells  lysates  stimu- 
lated by CD50, with anti-P-Tyr. 
Jurkat cells were incubated  with 
[3ZP]orthophosphate  for 3 h and 
stimulated by 152-2Dll, CD50 
(lane  1), Cris-7, CD3 (lane  2) and 
PMA (lane  3). Lane  4 shows  basal 
phosphoryhtion  without stimu- 
htion.  CD50 cross-linking  in- 
daces  tymsine-phosphoryhtion  of 
33- and 40-kD-specitic  substrates 
(a~s). 
subjected to phosphoamino add anaiysis which showed a phos- 
phoryhtion on tyrosine residues (Fig. 6 B). To further confirm 
these results, an in vitro kinase assay with 1% digitonin buffer 
was performed. This procedure produced a stronger and more 
complex pattern of  phosphorylation, which also included the 
31-kD molecule. The kinase activity was also  washed out 
by using 1 M  MgC12 solution (Fig.  6 C), thus confirming 
the previous observation.  Negative controls with mAb against 
unrelated Jurkat molecules (CD7 and CD27) did not show 
any kinase activity. Among the phosphorylated proteins there 
were two phosphoryhted molecules whose molecular masses 
suggested that they could correspond to the previously de- 
scribed PTK,  p56  ~,  and p59~.  Generally both  PTK be- 
come autophosphoryhted (32, 40) in in vitro kinase assays, 
and those labeled bands on the digitonin pattern could cor- 
respond to them. To better characterize the tyrosine kinase-as- 
sociated activity and to confirm the presence of lck and/or 
fyn PTK,  the immunoprecipitates were tested by Western 
blotting analysis with anti-lck and anti-fyn rabbit antisera. 
Fig. 7 shows that CD50 mAb coimmanoprecipitated both 
a 56-kD lck protein and a 59-kD fyn PTK. 
Discu~don 
Identified as ICAM-3,  an adhesion molecule involved in 
the initiation of immune responses,  the role of CD50 seems 
restricted to being a new counter-receptor of LFA-1, a main 
molecule in leukocyte  interactions (1, 2). In spite of the resem- 
blances to the other ICAMS, important CD50 differences (cell 
distribution, cell inductions, intracytoplasmic domain, phos- 
phorylation by PKC stimulation) lead us to suggest a different 
role for this molecule, probably through its intracytoplasmic 
domain. 
In this paper, data are presented showing that an ICAM 
molecule, CD50 (ICAM-3), is able to transduce signals  in 
a T cell line. One of the most outstanding characteristics of 
this  signal  transduction is  the Ca  2+  mobilization.  Assays 
using CD50 and CD3 mAb eross-linking (Fig.  1) allowed 
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ated with  immunoprecipitates of 
CDS0. (A) In vitro I~inase assay  of 
immunola'ecipitates from Triton 
X-100 lysates:  143-14  (CD27; nega- 
five  control,  lane I);  101-1D2 
(CD50, lane 2); 152-21)11  (CD50, 
lane 4); and 140-11  (CDS0, lane 6). 
CDS0  immtmoptedpitates  wae also 
analyzed after washing out with 1 
M MgCh:  101-11)2 (lane 3); 152- 
ZDll (h~ ~; and 140-11  (lane 7). 
Anmo shows a 31-kD pbosphory- 
hted molecule. (B) Phosphoamlno- 
acid analysis of a 31-kD molecule 
(p31). (C) In vitro kinase assay of 
CDS0  immuuoprecipitates  from 
digitonin lysates: 124-1D1 and 143- 
14 (CD7 and CD27 respectively; 
negative controls, lanes 1 and 2); 
101-1D2 (CD50, lane 3); 152-21)11 
(CDS0, lane  5); and 140-11  (CDS0, 
lane 7). CDS0 immunoprecipitates 
wm aho analy-zed  ~  washing out 
with  1 M  MgCh:  101-11)2 (lane 
4);  152-2Dll  (lane 6); and 140-11 
(lane  8).  Arrows show two phos- 
phoryhted molecule, probably cor- 
responding to autophosphoryhtion 
of lck and fyn FrK. 
Figure  7.  Western  blot analyss of CD50 immunoptecipitates  with rabbit 
polyclona/antiserum  to p59~ (A) and p56  kk (B). Total lysate of Jurkat 
(lane 1); immunoprecipitates  of 101-11)2 (CD50, lane 2), 152-2Dll (CD50, 
lane 3), 140-11 (CD50, lane 4), and 143-14  (CD27, lane 5, negative  control). 
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us to compare both signaling pathways. The most striking 
difference is that the CD50 mAb produces a slower, blunter, 
and steadier increase  of Ca  2  + than the CD3 mAb. From the 
data shown in Pig.  3 B, it comes out that  both CD3 and 
CDS0 mAb mobilize Ca  2+  from both sources, that  is,  in- 
ternal stores and extracellular input;  however, it seems that 
the extracellular  Ca  2§  mobilization,  through  CD50 mAb 
stimulation,  is more intense and prolonged than the release 
of intracellular  stores.  Moreover, the effect of simultaneous 
stimulation with CD3 and CD50 mAbs (Pig. 3 A) showed 
an  increase  of [Ca2+]i  that  was  more  complex  than  the 
simple addition  of each individual  stimulation.  These two 
sets of data,  analysis  of the Ca  2+  sources and costimulation 
with CD3 and CDS0 mAb, suggest that both stimulating 
molecules involve both, a common as well as a different signal 
transduction  pathway. 
Regarding  the  factors  that  regulate  Ca  2+  mobilization, 
from the results presented in this paper, it appears that both 
IPo  metabolism  and  phosphorylation  are  playing  a  role. 
Taking  into  consideration  both,  the  IPo  increase  and  the 
Ca  2+  mobilization from the internal  stores, it appears that 
the low participation  of the intracellular  stores could be as- 
sociated  with  the  low  levels  of IP3  observed  after  CD50 
cross-linking.  Furthermore,  the complete blockade of Ca  2+ 
uptake in the presence ofPTK inhibitors (Herbimycin A and 
Genistein),  suggests that a PTK activity could be associated 
with CD50. In addition, in vitro kinase assays of CD50 im- 
munoprecipitates showed the presence ofa kinase activity as- 
sociated with CD50 rather than inherent in the CD50 mole- 
cule.  Moreover, a PTK stimulation was also responsible for a very important increase of the tyrosine phosphorylation of 
several substrates including a 33- and a 40-kD proteins. This 
40-kD protein could be the equivalent to the substrate ob- 
served after CD2  and CD3  stimulation (41). Finally, the 
Western blot analysis  with specific  antisera against two well- 
characterized FFKs, p56  kk, and p59~, suggest that both ki- 
nases could be involved in CDS0 signaling processes. This 
double association could explain two phosphorylated bands 
present in the phosphorylation pattern of in vitro kinase assays 
developed in digitonin detergent conditions.  As was previ- 
ously described,  fyn and lck PTKs  generally become an- 
tophosphorylated upon activation (32, 40). Thus, their pres- 
ence, on an immunoprecipitation, is detected as phosphoryhted 
molecules when a in vitro kinase assay is performed (Fig. 4 
C, arrows). Although a defined membrane molecule has usu- 
ally been associated exclusively with one of the two FIXs, 
the simultaneous association of both kinases has also been 
described with TCR-CD3 (42), CD55, a phosphatidylino- 
sitol [inked membrane protein (43), and also recently with 
CD2 (44). These data raise the question about the different 
roles played by p56  ta and p59~.  However, taking into ac- 
count the differential expression of these PTKs on the hema- 
topoietic ceUs, a different PTK association of CD50 on the 
different hematopoietic lineages could easily be assumed. In 
this context, the broad distribution of CD50 molecuh could 
imply a different functional rule of CD50 in each kind of  cell. 
How CD50 interacts with both PTKs is one of the most 
interesting  aspects to  be  analyzed.  In the absence of ex- 
perimental data, we could assume that the intracytoplasmic 
domain is responsible for CD50 binding with both PTKs. 
The interaction between CDS0 and the different PTKs could 
be regnlated through CDS0 serine phosphorylations,  in a 
similar way as the one that has been described for CD4 mol- 
ecnle. CD4, like CD50, presents three phosphorylated serine 
residues when T  cells are activated by antigen or phorbol 
esters (45). These serines are placed next to the p56  ~k rec- 
ognition site in the CD4 molecule (46). However, the char- 
acteristic cysteine motif (46) of lck-CD4/CD8 interaction is 
not present in CD50. Likewise,  an indirect association  of  CD50 
with a muhimolecular complex formed by the antigen re- 
ceptor, CD4 or CDS, HLA, CD2, and CD5 (47) could not 
be ruled out. Moreover, we have observed that when CD50 
mAb are co-cross-linked with CD45 mAb, the functional 
effects of CD50 are abrogated (Fig. 4 C). That means that 
the function of the CD50-assodated  PTKs seems to be regu- 
lated by CD45 phosphatase. 
It is important to point out that the CD50 signal trans- 
duction capacity, described in this paper (Ca  2  + mobilization 
or PTK activity induction), is dearly observed by using both 
101-1D2 and 152-2Dll mAbs. These two mAbs recognize 
two different CD50 epitopes not related to LFA-1 binding 
(3). In contrast,  the mAb 140-11, which recognizes an epi- 
tope critical for LFA-1 binding (3), has been shown to be 
unable to transduce signals in the assays used in this study. 
In any case, all three CD50 mAbs used were able to coim- 
munoprecipitate  FTK activity as well as p56  l~k and p59~. 
Taking into account that certain differences in the affinities 
of the mAb have been observed (152-2D11>101-1D2>140- 
11) (Juan, M., unpublished observation), these differences  could 
be responsible for their different activation capability. How- 
ever, all these data could also be interpreted by considering 
that the induction of conformational changes produced by 
101-1D2 and 152-2Dll mAbs on CD50 molecule are neces- 
sary to induce intraceUular signaling. A similar situation has 
been previously described with other differentiation antigens 
such as CD2 (48) and CD45 (49), where, depending on the 
epitope recognized, a different functioml effect was observed. 
It should also be noted that the transduction of signals 
could be a bidirectional process, where the binding of CDS0 
to its counter-receptor, LFA-1, would trigger both molecules 
to send intracellular signals that would help in the cell acti- 
vation process. It has also been observed that CD50 cross- 
linking induced CD25 expression and IL-2 production after 
PMA  stimulation  (Juan,  M.,  M.  K.  Pino-Otfn,  and  E. 
Martfnez-C~ceres, unpublished data). Furthermore, experi- 
ments carried out recently in our laboratory, concerning the 
role of CD50 in lymphocyte-endothdium adhesion and homo- 
typic aggregation (50) showed that CDS0 stimulation is able 
to enhance B1 and B2 integrin function in T lymphocytes. 
These data, together with the data described in this paper, 
strongly suggest that CDS0 (ICAM-3) is not only a counter- 
receptor for LFA-1, but it is also by itself a functionally  rele- 
vant signaling molecule. 
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